PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC 50 s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner. PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Glucose Metabolism | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Casein Kinase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.